BridgeBio Pharma Inc

+0.65 (+1.34%)
Products, Regulatory

BridgeBio Pharma Announces Updated Phase 2B Data For Encaleret In Autosomal Dominant Hypocalcemia Type 1

Published: 10/01/2021 21:14 GMT
BridgeBio Pharma Inc (BBIO) - Bridgebio Pharma Announces Updated Phase 2b Data for Encaleret in Autosomal Dominant Hypocalcemia Type 1 (adh1) Demonstrating Blood and Urine Calcium Normalization in Trial Participants.
Bridgebio - in Update From Phase 2b Open-label, Dose-ranging Study, 13 Adults With Adh1 With 9 Distinct Casr Variants Were Administered Encaleret.
Bridgebio Pharma - Calcitriol, Extra-dietary Calcium Supplementation Beyond Recommended Daily Intake Were Discontinued During Study.
Bridgebio Pharma - Plans to Engage With Regulatory Health Authorities to Discuss Design of a Phase 3 Registrational Study in Patients With Adh1.